The trial was conducted at 4 MsFlash network sites (Appendix 1). Participants were recruited from July 2009 to June 2010, primarily by mass mailing to age-eligible women on purchased mailing lists or health-plan enrollment files. Eligible women were ages 40–62 years, in the menopause transition (amenorrhea >=60 days in the past year), or postmenopausal (>=12 months since last menstrual period or bi-lateral oophorectomy), or had a hysterectomy with one or both ovaries remaining and FSH >20 mIU/mL and estradiol <=50 pg/mL; and were in general good health as determined by medical history, a brief physical exam and standard blood tests. The required hot flash criteria were >=4 hot flashes or night sweats per day (24 hours) (an average of >=28 hot flashes/night sweats per week) recorded on daily hot flash diaries for 3 weeks in the screening period. Hot flashes/ night sweats had to be rated as bothersome (moderate or a lot) or severe (moderate or severe) on 4 or more days per week. Exclusion criteria included use of psychotropic medications, prescription, over-the-counter, or herbal therapies for hot flashes in the past 30 days; hormone therapy, hormonal contraceptives, selective estrogen receptor modulators (SERMs) or aromatase inhibitors in the past 2 months; current severe medical illness, major depressive episode, drug or alcohol abuse in the past year; suicide attempt in the past 3 years; lifetime diagnosis of bipolar disorder or psychosis, uncontrolled hypertension, history of endometrial or ovarian cancer, myocardial infarction, angina or cerebrovascular events or lack of non-hormonal contraception if sexually active and not postmenopausal.
Partial Protocol Preview
This section provides a glimpse into the protocol. The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Freeman E.W., Guthrie K.A., Caan B., Sternfeld B., Cohen L.S., Joffe H., Carpenter J.S., Anderson G.L., Larson J.C., Ensrud K.E., Reed S., Newton K.M., Sherman S., Sammel M.D, & La Croix A.Z. (2011). Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA : the journal of the American Medical Association, 305(3), 267-274.
Hot flashes or night sweats per day (24 hours) (an average of >=28 hot flashes/night sweats per week)
Severity of hot flashes/night sweats (moderate, a lot, or severe) on 4 or more days per week
control variables
Age (40–62 years)
Menopausal status (in the menopause transition, postmenopausal, or had a hysterectomy with one or both ovaries remaining and FSH >20 mIU/mL and estradiol <=50 pg/mL)
General health (as determined by medical history, a brief physical exam and standard blood tests)
Use of psychotropic medications, prescription, over-the-counter, or herbal therapies for hot flashes in the past 30 days
Use of hormone therapy, hormonal contraceptives, selective estrogen receptor modulators (SERMs) or aromatase inhibitors in the past 2 months
Current severe medical illness, major depressive episode, drug or alcohol abuse in the past year
Suicide attempt in the past 3 years
Lifetime diagnosis of bipolar disorder or psychosis
Uncontrolled hypertension
History of endometrial or ovarian cancer, myocardial infarction, angina or cerebrovascular events
Lack of non-hormonal contraception if sexually active and not postmenopausal
positive controls
None specified
negative controls
None specified
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required